Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced the Last Patient First Visit in its CANYON-1 Phase 1b study of CRB-913 for obesity on April 14, 2026. The 16-week, double-blind, placebo-controlled, dose-ranging trial enrolls 240 obese, non-diabetic participants across 20 mg, 40 mg, and 60 mg cohorts.

The study is on track for completion in summer 2026, with participants dosed for three months and monitored one month post-dosing; Phase 1b will build on Phase 1a weight-loss signals.

News Market Reaction – CRBP

-1.57%

-1.57% Session close to close

In the Apr 14 session, CRBP declined 1.57%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement marks full enrollment with Last Patient First Visit in the 16‑week, n=240 CANYON‑1...

Analysis

This announcement marks full enrollment with Last Patient First Visit in the 16‑week, n=240 CANYON‑1 Phase 1b study of CRB‑913 for obesity, building on Phase 1a data showing nearly 3% weight loss at 14 days. It reinforces Corbus’s dual focus on oncology and obesity, supported by $163.3M in year‑end 2025 cash and an effective $300,000,000 shelf. Investors may watch for Phase 1b efficacy, tolerability, and any subsequent financing steps as key next checkpoints.

Key Figures

Phase 1b sample size: n=240 participants Study duration: 16-week Phase 1b Early weight loss: nearly 3% at 14 days +5 more

8 metrics

Phase 1b sample size n=240 participants CANYON-1 obesity study design

Study duration 16-week Phase 1b CANYON-1 dose-finding trial

Early weight loss nearly 3% at 14 days Phase 1a obesity findings cited in release

Placebo-adjusted weight loss 2.9% at Day 14 CRB-913 obese cohort, Phase 1a SAD/MAD

Year-end cash $163.3M Cash, cash equivalents and investments at end of 2025

2025 net loss $78.5M Full-year 2025 net loss

2025 R&D spend $70.1M Full-year 2025 research and development expenses

Shelf registration size $300,000,000 S-3 shelf to offer securities

Historical Context

5 past events · Latest: Apr 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 07	FDA alignment for CRB-701	Positive	-4.2%	FDA alignment on registrational designs for CRB-701 in HNSCC and cervical cancer.
Mar 18	Conference / obesity update	Positive	-6.0%	Metabolic Health Summit participation and CRB-913 Phase 1a data with planned Phase 1b.
Mar 09	Earnings & pipeline update	Positive	+19.2%	Q4/2025 results, strong CRB-701 and CRB-913 signals, $75M offering and $163.3M cash.
Feb 12	Conference presentation	Neutral	+2.8%	Oppenheimer conference corporate overview and investor meetings announcement.
Jan 05	J.P. Morgan conference	Neutral	-0.5%	J.P. Morgan Healthcare Conference presentation and one-on-one investor meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: one earnings/clinical update drew a strong gain, while other seemingly positive catalysts, including regulatory alignment and obesity updates, saw selling pressure.

Recent Company History

Over the past few months, Corbus has highlighted progress across oncology and obesity, including FDA alignment on CRB-701 registrational paths (Apr 7, 2026) and multiple conference appearances. The Q4/2025 results on Mar 9, 2026 combined encouraging efficacy signals for CRB-701 and CRB-913 with strengthened cash of $163.3M, and that update saw a 19.23% gain. By contrast, earlier obesity and conference communications in March produced negative price reactions, suggesting investor responses to positive news have been uneven. Today’s obesity trial enrollment milestone fits into this ongoing clinical execution narrative.

Key Terms

phase 1b, double-blind, placebo-controlled, dose-ranging, +4 more

8 terms

phase 1b medical

"CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

double-blind medical

"16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese..."

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese..."

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

dose-ranging medical

"16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese..."

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

cb1 inverse agonist medical

"highly peripherally restricted oral CB1 inverse agonist potentially offering..."

A CB1 inverse agonist is a drug that binds to the brain and nervous system’s CB1 cannabinoid receptor and pushes its activity below its normal resting level, producing effects opposite to those of cannabis-like stimulation. For investors, these drugs matter because altering appetite, mood, pain or addiction pathways can create significant market opportunities or regulatory risks—think of it as turning a dimmer switch lower than the factory setting to achieve a different therapeutic outcome.

glp-1s medical

"Despite the remarkable success of GLP-1s and the incretin class, significant..."

GLP-1s are a class of prescription medicines that mimic a natural gut hormone to lower blood sugar, curb appetite and slow stomach emptying, often used for diabetes and weight management. They matter to investors because prescribing rates, pricing and insurance coverage can drive large, sustained revenue streams and reshape demand across drug makers, medical device vendors and health insurers—like a bestselling product line that shifts an entire market.

incretin medical

"Despite the remarkable success of GLP-1s and the incretin class, significant..."

Incretins are natural hormones released by the gut after eating that tell the pancreas to release insulin and help lower blood sugar; think of them as the body's meal-time alert system for managing glucose. Investors care because many diabetes and weight-loss drugs mimic or affect incretins, so changes in incretin science, drug success, safety or regulatory decisions can directly influence pharmaceutical sales, treatment adoption and company valuations.

placebo cohort medical

"The trial includes a placebo cohort and three CRB-913 cohorts of 20 mg, 40 mg..."

A placebo cohort is the group of participants in a clinical trial who receive an inactive substance or sham procedure instead of the investigational treatment, serving as a baseline to measure real drug effects. For investors, the makeup and outcomes of the placebo cohort matter because they reveal how much of a drug’s apparent benefit is genuine versus due to chance or perception, which directly affects trial success, regulatory approval odds, and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026

Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals with obesity

CRB-913 is a non-incretin daily oral small molecule with the potential to deliver a therapeutic option for weight loss and long-term weight management

NORWOOD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced the last patient has been enrolled and completed the first clinical visit (Last Patient First Visit) in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track to be completed in the summer of 2026. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management.

The CANYON-1 Phase 1b clinical trial is a 16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic participants, and is being conducted at multiple clinical sites in the United States. The trial includes a placebo cohort and three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily (QD). A dose titration regimen is included in the design, with all CRB-913 participants commencing at 20 mg/day and then titrating up to either 40 mg/day or beyond that to 60 mg/day, depending on their respective cohorts. Participants are dosed for 3 months and are then monitored for an additional month post-dosing.

“Despite the remarkable success of GLP-1s and the incretin class, significant treatment gaps exist for millions of people struggling with obesity. In the real-world setting, over 40% of those who try incretin therapy turn out to be either intolerant or non-responsive to these drugs. These factors contribute to the high discontinuation rate of over 60% for this class. These statistics underscore the need for new, additional mechanisms to address obesity,” said Yuval Cohen, PhD, Chief Executive Officer of Corbus. “We look forward to our upcoming Phase 1b data readout that will help further inform CRB-913's potential to deliver a novel, non-incretin drug and therapeutic option for weight loss and long-term weight management.”

About the CRB-913 Phase 1a Study Findings

Corbus completed a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 in December 2025. The SAD portion of the trial enrolled 64 participants across 8 cohorts. The MAD portion enrolled 48 participants across 4 cohorts, including a dedicated obese cohort. The highest SAD dose tested was 600 mg/day, and the highest MAD dose tested was 150 mg/day. In the dedicated obese MAD cohort (150 mg/day), all CRB-913-treated participants (n=9), and none in the placebo group (n=3), experienced weight loss. The CRB-treated participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14. Weight loss started early and deepened with time. CRB-913 was safe and well-tolerated across all cohorts and all doses studied, including demonstrating a very favorable GI profile with no reports of vomiting, constipation or nausea. Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

FAQ

What is the CANYON-1 Phase 1b study for CRB-913 (CRBP) and its primary design?

CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging Phase 1b study in 240 obese, non-diabetic participants. According to Corbus, it includes a placebo arm and three CRB-913 cohorts dosed QD at 20 mg, 40 mg, and 60 mg with titration and one-month post-dosing follow-up.

When will Corbus (CRBP) complete the CANYON-1 Phase 1b trial and deliver data?

The study is on track to complete in summer 2026, with a Phase 1b data readout expected thereafter. According to Corbus, last patient first visit was completed April 14, 2026, supporting the planned summer 2026 finish and subsequent data analysis timeline.

What is CRB-913's mechanism and how does it differ from GLP-1 therapies for obesity?

CRB-913 is a peripherally restricted oral CB1 inverse agonist, offering a non-incretin approach to weight management. According to Corbus, it targets the endocannabinoid system rather than GLP-1 pathways, potentially serving patients intolerant or non-responsive to incretin drugs.

What dosing cohorts and titration schedule does the CANYON-1 trial (CRBP) use?

CANYON-1 includes three CRB-913 cohorts: 20 mg, 40 mg, and 60 mg once daily, with all participants starting at 20 mg/day then titrating up. According to Corbus, titration moves participants to 40 mg or 60 mg depending on cohort assignment, with three months dosing plus one month follow-up.

What does the Last Patient First Visit milestone mean for CRBP shareholders?

Last Patient First Visit indicates enrollment completion and that the trial is progressing toward scheduled data readout. According to Corbus, it supports the company’s timeline toward a summer 2026 study completion and a subsequent Phase 1b data release that investors may watch.